Name: ALKERMES PLC (ALKS) Stock
Brand: ALKERMES PLC
Rating: 5.5 (3 reviews)

ALKS Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Zacks Investment Research - Mentions: BMRN

Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report?

4 days ago - By: Alkermes plc

Alkermes to Participate in Two Upcoming Investor Conferences

9 days ago - By: Zacks Investment Research - Mentions: AGIO CRMD FULC

AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results

9 days ago - By: Zacks Investment Research - Mentions: CRMD AVDL CSTL

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal

10 days ago - By: Zacks Investment Research - Mentions: INSM CRMD CSTL

Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri

11 days ago - By: Stocktwits - Mentions: AVDL

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge

15 days ago - By: Investor's Business Daily - Mentions: AVDL

Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid

15 days ago - By: Alkermes plc

Alkermes Response to Avadel Announcement

10 days ago - By: Zacks Investment Research - Mentions: ALL MS TTWO SOFI

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

10 days ago - By: Zacks Investment Research - Mentions: JNJ FOLD

BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU

11 days ago - By: Alkermes plc - Mentions: AVDL

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

11 days ago - By: Zacks Investment Research - Mentions: LLY

RHHBY Reports Positive Phase III Data on Breast Cancer Drug

11 days ago - By: Zacks Investment Research - Mentions: JAZZ CRMD ZYME

JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data

11 days ago - By: Zacks Investment Research - Mentions: CRMD AVDL CSTL

Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal

18 days ago - By: Zacks Investment Research - Mentions: ILMN

ALKS or ILMN: Which Is the Better Value Stock Right Now?

12 days ago - By: Zacks Investment Research - Mentions: SRPT CRMD

FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings

15 days ago - By: Benzinga - Mentions: AVDL

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal

15 days ago - By: Zacks Investment Research - Mentions: GILD GSK FOLD

GILD's Investigational Regimen for HIV Treatment Meets Primary Goal

16 days ago - By: Stocktwits - Mentions: AVDL

Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes

16 days ago - By: Benzinga - Mentions: ENGN IMMP MLSS PHIO ...

12 Health Care Stocks Moving In Thursday's After-Market Session

16 days ago - By: Zacks Investment Research - Mentions: BMY FOLD CYTK

Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?

17 days ago - By: Alkermes plc

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2

18 days ago - By: Zacks Investment Research - Mentions: FOLD CRMD IMVT

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

18 days ago - By: Zacks Investment Research - Mentions: VRTX CRMD CRSP

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

22 days ago - By: Zacks Investment Research - Mentions: ANIP CRMD IOVA

IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y

22 days ago - By: Zacks Investment Research - Mentions: BIIB DNLI TAK

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug

22 days ago - By: Zacks Investment Research - Mentions: ALLO ANIP CRMD

Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales

22 days ago - By: Zacks Investment Research

Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?

23 days ago - By: Alkermes plc

Alkermes to Participate in Two Upcoming Investor Conferences

23 days ago - By: Zacks Investment Research - Mentions: ANIP CRMD RVMD

Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil

23 days ago - By: Zacks Investment Research - Mentions: JAZZ ANIP CRMD

JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View

23 days ago - By: Zacks Investment Research - Mentions: FOLD CRMD VTRS

Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance

24 days ago - By: Zacks Investment Research - Mentions: PRGO ANIP CRMD

Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut

24 days ago - By: Zacks Investment Research - Mentions: EXEL FOLD

EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales

24 days ago - By: Zacks Investment Research - Mentions: FOLD CRMD EXAS

Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues

25 days ago - By: Zacks Investment Research - Mentions: GILD GSK

ALKERMES PLC (ALKS) Stock News

ALKS Latest News, Press Relases and Analysis

Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report?

Alkermes to Participate in Two Upcoming Investor Conferences

AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal

Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge

Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid

Alkermes Response to Avadel Announcement

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

RHHBY Reports Positive Phase III Data on Breast Cancer Drug

JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data

Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal

ALKS or ILMN: Which Is the Better Value Stock Right Now?

FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal

GILD's Investigational Regimen for HIV Treatment Meets Primary Goal

Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes

12 Health Care Stocks Moving In Thursday's After-Market Session

Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug

Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales

Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?

Alkermes to Participate in Two Upcoming Investor Conferences

Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil

JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View

Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance

Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut

EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales

Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues

HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline